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Background: Surgery is the treatment of choice for colorectal cancer liver metastases (CLM). The aim of
our study was to analyze which clinical and pathological risk factors can predict recurrence after liver
resection.
Methods: Consecutive patients who underwent hepatic resection for CLM were studied retrospectively to
identify risk factors inﬂuencing cancer recurrence, by univariate and multivariable analyses.
Results: 97 patients (2004e2008) with a median age of 64.6 years (inter-quartile range 57.6e72.6) had
a median disease free survival of 16.4 months. On univariate analysis the largest metastasis >5 cm
(hazard ratio, HR 2.04, 95% CI 1.10e3.80, p ¼ 0.03), presence of extra-hepatic disease (HR 2.39, 95% CI
1.14e5.02, p ¼ 0.02) and a resection margin 5 mm (HR 1.91, 95% CI 1.06e3.47, p ¼ 0.03) were signif-
icantly associated with a higher risk of recurrence after curative resection for CLM. These were conﬁrmed
as independent predictors for recurrence on multivariable analysis. There were signiﬁcantly more
patients with lymph node negative (N0) primary in the group with liver secondary > 5 cm (n ¼ 18, 39%),
than in the group with liver secondary £5 cm (n ¼ 7, 14.6%) (p ¼ 0.01).
Conclusion: We demonstrated a positive correlation between N0 primary tumour and large liver
metastases, which have a higher risk of disease recurrence. If validated in larger, independent studies,
this study would suggest routine imaging surveillance follow up of even N0 colorectal tumours, until the
biology of these tumours is fully understood.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Five-year survival afterhepatic resectionof colorectalmetastases
ranges from 32% to 65% in the largest series.1e4 However, which
patientsbeneﬁtmaximally isunclear. Fonget al.,1 proposedaClinical
Risk Score (CRS) based on ﬁve criteria which were highly predictive
of poor outcome after resection of colorectal livermetastases: node-
positive primary tumour, disease free interval from primary to
discovery of metastases of <12 months, >1 liver metastases, pre-
operative CEA > 200 ng/ml and size of the largest tumour > 5 cm.
The predictive value of the CRS has been corroborated by only two
retrospective studies.5,6 The presence of 3 ormore of these criteria is
strongly associated with a poor prognosis. Others have suggested
that pre-operative prognostic factors such as theDuke’s stage status,PB Centre, The Royal London
44 20 7377 7491.
n.nhs.uk (H.M. Kocher).
ciates Ltd. Published by Elsevier Ltlymph node involvement and the grade of differentiation, the
presence of extra-hepatic disease6e10 and operative indicators such
as resectionmargins, aswell as extra-hepatic invasionare associated
with a higher risk of recurrence.4,11e23 Independent validation of
these criteria is lacking. The aim of our study was to analyze these
clinical and histological factors, including the CRS, and to evaluate
possible correlations with pre-operative and other independent
predictors, if any, with the outcome.2. Methods
All hepatic resections for CLM performed at the Barts & The
London HPB Centre during a 5-year period (January 2004 to
December 2008) were prospectively recorded in our database and
retrospectively analyzed. Data examined included demographics,
features of primary colorectal lesion, disease-free interval from the
primary to discovery of the liver metastases, histopathology of the
liver lesions and the surgical outcome.d. All rights reserved.
Table 1
Demographic, clinical and histological characteristics of 97 patients with colorectal
cancer liver metastases who underwent surgical resection.
Demographic and
clinical data
Variable Total (n ¼ 97)
n (%)
Gender
Male 56 (57.7%)
Female 41 (42.3%)
Age
Median, years (IQR) 64.6 (57.6; 72.6)
pre-operative CEA
Median, ng/mL (IQR) 9.2 ng/mL (3.1; 53.6)
Primary Tumour Site
Rectum 37 (38.1%)
Sigmoid Colon 35 (36.1%)
Right Colon 12 (12.4%)
Left Colon 7 (7.2%)
Transverse Colon 6 (6.2%)
Stage
Dukes A 4 (4.1%)
Dukes B 14 (14.4%)
Dukes C 34 (35.1%)
Dukes D 45 (46.4%)
Nodal status
Node negativea 25 (25.8%)
Node positive 72 (74.2%)
Synchronous metastases 45 (46.4%)
Metachronous metastases 52 (53.6%)
Adjuvant chemotherapy
Yes 82 (84.5%)
No 15 (15.5%)
Metastases features Tumour size
Median, cm (IQR) 5 cm (2.8; 10)
Resection margin
R0 76 (78.4%)
R1 21 (21.6%)
Grading
Well Differentiated 40 (41.2%)
Moderately Differentiated 51 (52.6%)
Poorly Differentiated 6 (6.2%)
Distribution
Unilobar 70 (72.2%)
Bilobar 27 (27.8%)
Number
Solitary 49 (50.5%)
Multiple 46 (47.4%)
a The number of node negative tumours is more than the sum of the Dukes A and
Dukes B tumours, as some of the Dukes D tumours were node negative as well.
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proposed by Fong et al.1 and the composite score as well as
individual factors were assessed for their effect on disease-free
survival. All patients underwent thoracic, abdominal and pelvic
computed tomography (CT) and Positron Emission Tomography
(PET) scan prior to liver resection and were discussed at a weekly
hepatobiliary multi-disciplinary meeting to determine the size,
location and number of deposits. Portal vein embolization (PVE)
was performed in selected cases when functional remnant liver
after planned resection was deemed to be too small (<0.5 ml/kg
body weight). All the operations were performed by four experi-
enced hepatobiliary surgeons (ATA, RRH, SB and HMK) and in the
majority of patients, intraoperative ultrasound (IOUS) was used for
localization of the tumour and conﬁrmation of vasculature and
biliary anatomy.
Morbidity was deﬁned as any peri-operative complication that
prolonged the hospital stay or needed active management. Peri-
operative mortality was deﬁned as any in-hospital death or death
within 30 days when patients were discharged from the hospital
earlier. Patients were followed up at regular intervals after
discharge. Follow up data was obtained by review in the out-
patient clinic or by telephone clinic run by clinical nurse specialist
(KM). Recurrence was deﬁned as presence of radiologically
conﬁrmed metastases with histological conﬁrmation, whenever
possible. To ascertain complete histological evaluation of tumours
specimen, we obtained full histology report of primary tumours
(mostly carried out in other hospitals). Histology reports were
available for 90 of 97 patients and demonstrated complete lymph
node staging as per international guidelines.
2.1. Statistical analysis
Distribution of continuous variables were reported as median
and inter-quartile range (IQR) (25th; 75th percentiles), and cate-
gorical variables are presented as numbers and percentages. The
comparison between subgroups, identiﬁed by status at end of
follow-up (disease recurrence), was carried out using Student’s
t test, or ManneWhitney U test, for continuous variables. Qualita-
tive data were compared by the Chi-square test or Fischer’s exact
test as required. Survival probability was estimated according to the
KaplaneMeier method, whereas the log-rank test was used for
comparison of survival in different subgroups. Univariate and
Multivariate analysis was performed using the Cox-regression
model to evaluate signiﬁcant predictors of recurrence and their
relative role. Statistical analyses were performed using SPSS 16.0
for Windows software (SPSS Inc, Chicago, Illinois, USA). P  0.05
was considered signiﬁcant.
3. Results
Ninety-seven patients underwent liver resections for CLM over
5 years at our institution; demographic, clinical and histological
data are summarized in Table 1. After ﬁrst liver resection, 6 (5.7%)
patients underwent surgery for another resection and 2 (2.9%) had
a third operation. Thirteen (13.4%) patients underwent PVE prior to
surgery and 11 (11.3%) had extra-hepatic disease. Sixty-four (66%)
patients had a CRS  2 whereas 33 (34%) patients had a CRS>2.
Among the 105 liver resections, in 52 (49.5%) patients a major
hepatectomy was performed, 27 (25.7%) patients underwent
a segmentectomy and 26 (24.8%) a wedge resection; in 13 (12.4%)
patients a radio-frequency ablation (RFA) was carried out during
the operation, as an adjunct to hepatectomy. The median blood loss
was 700 ml (IQR 350; 1000 ml) and 32 (30.5%) patients had
complications. Bile leak was the commonest complication (10.5%).
The median length of hospital stay was 9 days (IQR 7; 15 days) andperi-operative mortality occurred in 6 (5.7%) patients. On patho-
logical examination, the median size of the largest tumour was
5 cm (IQR 2.8; 10 cm) and a R0 resection was conﬁrmed in 76
(78.4%) patients while 21 (21.6%) had a R1 resection. Seventy-nine
(81.4%) patients were alive, 17 (17.5%) were deceased and 1 patient
(1%) was lost at follow up at the end of June 2009 and 44 (45.4%)
patients had a recurrence after curative liver resection for colorectal
metastases.
The 3-and 5-years disease-speciﬁc survival from the resection
of the primary tumour were 81.3% and 72.6% respectively,
whereas the 3-years disease-speciﬁc survival from the resection
of the liver metastases was 64.5%. The 3-years disease-free
survival was 23% with a median of 16.4 months (Fig. 1). On
univariate analysis (Table 2), the largest metastasis >5 cm, the
presence of extra-hepatic disease and a resection margin 5 mm
were signiﬁcantly associated with a higher risk of recurrence
after curative resection for CLM.
Multivariable analysis conﬁrmed that the presence of a lesion
with a diameter > 5 cm, and a resection margin 5 mm as inde-
pendent prognostic indicators of recurrencewith presence of extra-
hepatic disease just reaching the signiﬁcant threshold (Table 3). The
estimated disease-free survival curve based on each factor is shown
in Fig. 2. The hazard ratio was slightly, but not signiﬁcantly higher
Fig. 1. Disease-free survival of patients (n ¼ 97) after curative liver resection for
colorectal liver metastases.
Table 3
Multivariable analysis of prognostic factors for recurrence after liver resection for
CLM.
Variable HR 95% CI p
Presence of extra-hepatic disease 2.03 0.99 4.14 0.05
Size of the largest metastases > 5 cm 2.17 1.19 3.96 0.01
Margin 5 mm 2 1.08 3.69 0.03
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95% 0.97e3.06).
On the basis of these results, we divided our cohort of patients
into two different groups; group A included patients with a largest
liver lesion5 cm and group B included patients with a largest liver
lesion > than 5 cm Table 4 compares the pre-operative ﬁndings
between the two groups, which demonstrates no differences
between the two groups for most variables. Surprisingly, 85.4% of
patients with smaller tumours (Group A) had lymph node
involvement at the time of the resection for the primary tumour
whereas only 61% of patients with large liver metastasis (Group B)
had histologically conﬁrmed lymph node involvement at the time
of the primary resection (p ¼ 0.013). Within the group of patients
with negative lymph nodes at the ﬁrst diagnosis, 7 (28%) had
synchronous metastases whereas 18 (72%) developed metachro-
nous metastases (p ¼ 0.03).Table 2
Univariate analysis of prognostic factors for recurrence after liver resection for CLM.
Variable HR 95% CI p
Gender (Male vs. Female) 1.39 0.75 2.59 0.30
Age > 60 years 1.69 0.80 3.58 0.17
pre-operative CEA > 200 ng/mL 2.48 0.57 10.74 0.23
Presence of extra-hepatic disease 2.39 1.14 5.02 0.02
Microvessel Invasion 1.04 0.13 8.22 0.97
Primary Site Rectum 1.28 0.03 2.48 0.26
Sigmoid Colon 1.12 0.41 3.01 0.83
Left Colon 0.58 0.14 2.45 0.46
Transverse Colon 0.29 0.03 2.48 0.26
Right Colon reference
Dukes D 0.42 0.12 1.46 0.17
Dukes C 0.45 0.13 1.59 0.22
Dukes B 0.71 0.18 1.59 0.62
Dukes A reference
Primary tumour N1 0.70 0.35 1.40 0.70
Metachronous 0.43 0.70 2.33 0.43
Interval  12 months 1.16 0.61 2.17 0.66
Size of the largest metastases > 5 cm 2.04 1.10 3.80 0.03
Number of metastases > 1 0.97 0.53 1.77 0.92
Grading Poorly Differentiated 2.56 0.83 7.92 0.10
Moderately Differentiated 1.75 0.91 3.66 0.09
Well Differentiated reference
Distribution (Bilobar) 0.79 0.41 1.52 0.48
Margin 5 mm 1.91 1.06 3.47 0.03
CRS > 2 1.72 0.97 3.06 0.074. Discussion
Our study conﬁrmed that surgery is an effective treatment for
CLM with a 3-years disease-speciﬁc survival of 64.5%, consistent
with other studies.24e26 In the current study, a resection margin
5mm, size of the largest liver metastasis> 5 cm, and the presence
of extra-hepatic disease were independent predictors of recurrence
after curative resection for CLM. Previously, a resection margin less
than 1 cm for CLM has been shown to decrease disease-free
survival.14,21,23,27,28 Furthermore, others have found that a resection
margin greater than 5 mm is an independent favourable prognostic
factor.15Fig. 2. Comparison of the disease-free survival of patients undergoing liver resection
based on the signiﬁcant prognostic factors. a) Patients with largest metastasis 5 cm
(n ¼ 50, continuous line) and patients with largest metastasis >5 cm (n ¼ 47, dotted
line); (p ¼ 0.01). b) Resection margin > 5 mm (continuous line) versus resection
margin 5 mm (dotted line); (p ¼ 0.03).
Table 4
Comparison between two groups of patients with the diameter of the largest liver metastasis 5 cm (group A) and patients with the diameter of the largest liver metastasis
>5 cm (group B).
Variable Group A (n ¼ 50) Group B (n ¼ 47) p Test
Men (n) 27 (51.9%) 32 (64%) 0.22 Chi-Square Test
Age (median,IQR) 62.15 years
(56.6; 73.16)
67.61 years
(53.19; 71.78)
0.29 ManneWhitney U Test
pre-operative CEA (median,IQR) 20.6 ng/mL
(3.25; 96.52)
8.5 ng/mL
(3.2; 44.2)
0.48 ManneWhitney U Test
Site Primary
Right Colon 4 (8.3%) 6 (13%) 0.87 Fisher’s Exact Test
Transverse Colon 4 (8.3%) 2 (4.3%)
Left Colon 3 (6.2%) 4 (8.7%)
Sigmoid Colon 18 (37.5%) 16 (34.8%)
Rectum 19 (39.6%) 18 (39.1%)
Dukes A 2 (4.2%) 2 (4.3%) 0.22 Fisher’s Exact Test
Dukes B 4 (8.3%) 10 (21.7%)
Dukes C 21 (43.8%) 13 (28.3%)
Dukes D 21 (43.8%) 21 (45.7%)
N1 (primary tumour) N0 (primary tumour) 41 (85.4%) 7 (14.6%) 28 (61%) 18 (39%) 0.01 Chi-Square Test
Adjuvant chemotherapy (n) 39 (81.2%) 40 (87%) 0.45 Chi-Square Test
Synchronous presentation Metachronous presentation 21 (43.8%)
27 (56.2%)
21 (45.7%)
25 (54.3%)
0.85 Chi-Square Test
Months from primary to metastases (median) 11 months 12 months 0.58 ManneWhitney U Test
Margin, mm (median,IQR) 4.5 mm (1; 10.75) 8.5 mm (0.88; 13.5) 0.29 ManneWhitney U Test
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proposed by Fong et al.,1 is a signiﬁcant predictive factor for
recurrence after liver resection for CLM. However, among the ﬁve
criteria,1 the largest metastases with a diameter > 5 cm is most
frequently found to be a negative prognostic factor18,25,29e31 and
has been conﬁrmed by our cohort of patients. Beyond the study
from the Memorial Sloane Kettering,1 many reports suggested that
the diameter of the largest metastasis is a predictive factor of
recurrence after surgery.7,18,25,30 Tanaka et al.,30 suggested that
apart from the size of the metastasis, a short CLM doubling time
(<45 days) negatively affects the survival as well.
In order to ascertain the prognostic relevance of this factor, we
choose to analyze the pre-hepatectomy factors that could be
associated with a larger metastasis size. We compared two groups
of patients using 5 cm diameter of the largest metastasis as cut off
and found that the median time from diagnosis of the primary
tumour and the detection of liver metastases was no different
between two groups. This fact seems to demonstrate that the larger
lesions grow more quickly than the smaller ones and this could be
related to a more aggressive biological behaviour i.e. shorter
tumour doubling time. Interestingly, the number of patients
without lymph nodes involvement at the time of primary tumour
resection is higher in the group with larger CLM and several
possible hypotheses could explain this ﬁnding.
Firstly, patients with N0 primary colon cancer usually have
less stringent follow-up criteria following resection of the
primary tumour. The current guidelines for the surveillance and
follow-up of patients with colorectal cancer recommend routine
clinic visits and CEA measurements without routine hepatic
imaging.32,33 In our two groups, we failed to ﬁnd a statistically
signiﬁcant difference between the median pre-operative CEA
values (Table 4). Therefore, CEA may not predict the size of the
metastases and in the absence of a routine surveillance hepatic
imaging studies some patients could develop large lesions within
a relatively short period of time. In both groups the rate of
adjuvant chemotherapy was the same and this reassures us that
N0 patients were not under-treated. Perhaps, dedicated protocol
use of imaging studies, such as abdominal ultrasound, could
detect these metastatic lesion(s) earlier and neo-adjuvant
chemotherapy trials for liver resection such as new-EPOC can
treat these patients better.Another possible explanation of larger hepatic metastases with
N0 primary may be related to a preferential haematogenous spread
for a subgroup of tumours and resulting in a greater size of the ﬁnal
metastatic nodules. The TNM-system of the International Union
against Cancer34 does not allow precise prognostication for an
individual patient and to overcome this limitation, molecular
characterization of the tumour have been advocated.35 In order to
identify patients with Dukes’ B colon cancer at high risk of recur-
rence, Wang et al.36 identiﬁed a 23-gene signature that predicts
recurrence in Dukes’ B colon cancer. Moreover, a study from the
University of Heidelberg37 suggested that the detection of circu-
lating tumour cells in blood samples of patients with stage II
colorectal cancer can identify patients with a poor outcome. These
ﬁndings indicate that a particular subgroup of colorectal tumours,
though without lymph node metastases, can have an aggressive
biological behaviour.
Another possible reason for the association between colorectal
N0 tumours and larger size of liver metastases could be the pres-
ence of lymph node or hepatic micrometastases. The detection of
micrometastases in stage II colorectal cancer is a prognostic tool
and can explain the high incidence of recurrence in some patients
without lymph nodes metastases after curative resection of the
primary colorectal cancer.38
Our study has several limitations; ﬁrst of all, this is a retro-
spective review of a relatively small series of patients. Secondly, the
short follow up does not allow proper evaluation of long term
disease-speciﬁc survival, although considering the presence of
recurrence as an event should not bias our results. Lastly, since
many patients were referred from different institutions, they were
not followed up with a standard protocol after the primary cancer
resection.
In conclusion, we conﬁrmed that the presence of extra-hepatic
disease, a resection margin less than 5 mm and a diameter of the
largest metastasis more than 5 cm are negative prognostic factors
for recurrence after curative resection for CLM. Given the higher
number of patients with N0 primary tumour in the group of
patients with the larger metastatic lesions, we suggest that perhaps
a more routine use of imaging modalities such as abdominal
ultrasound may have helped in early detection. Our observations
should be validated in multi-centre, prospective studies with
uniform post-primary resection surveillance protocol.
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